Journal article
Targeting beta III-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics
Anti-cancer agents in medicinal chemistry, v 11(8), pp 719-728
01 Oct 2011
PMID: 21707498
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Glioblastoma multiforme (GBM) is the most common, aggressive, and chemorefractory brain tumor in human adults. Notwithstanding significant discoveries in the elucidation of pathways of molecular signaling and genetics of GBM during the past 20 years there has been no breakthrough in the pharmacological treatment of this high-grade malignancy. We, and others, have previously demonstrated increased expression of beta III-tubulin in GBM asserting a link between aberrant expression of this beta-tubulin isotype and a disruption of microtubule dynamics associated either with malignant tumor development de novo, or with progression and malignant transformation of a low-grade glioma into GBM. This article reviews beta III-tubulin as a promising target in the experimental treatment of GBM and examines the potential use of epothilones, a new family of anticancer agents shown to be active in beta III-tubulin-expressing tumor cells, as well as the "double hit" therapeutic concept of tumor cell sensitization to tubulin binding agents (TBAs) by beta III-tubulin silencing. The latest progress regarding the function and potential role of beta III-tubulin in aggressive tumor behavior, cancer stem cells, tumor cell hypoxia, and resistance to taxane-related compounds, is also critically appraised.
Metrics
Details
- Title
- Targeting beta III-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics
- Creators
- Christos D. Katsetos - St. Christopher's Hospital for ChildrenPavel Draber - Cytoskeleton (United States)Maria Kavallaris - Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Randwick, NSW, Australia
- Publication Details
- Anti-cancer agents in medicinal chemistry, v 11(8), pp 719-728
- Publisher
- Bentham Science Publ Ltd
- Number of pages
- 10
- Grant note
- P302/10/1701 / Grant Agency of the Czech Republic New South Wales Cancer Council; Cancer Council New South Wales Children's Cancer Institute Australia for Medical Research with the University of New South Wales Sydney Children's Hospital 203 / St. Christopher's Foundation for Children NHMRC; National Health and Medical Research Council (NHMRC) of Australia
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000298057800005
- Scopus ID
- 2-s2.0-80053555640
- Other Identifier
- 991019346800804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Chemistry, Medicinal
- Oncology